Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease
- PMID: 24811546
- DOI: 10.1007/s40265-014-0215-7
Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease
Abstract
Sevelamer carbonate (Renvela(®)), a buffered form of sevelamer hydrochloride (Renagel(®)), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥ 1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.
Similar articles
-
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22. Nephrol Dial Transplant. 2014. PMID: 24151017 Clinical Trial.
-
Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Pharmacotherapy. 2009. PMID: 19397463 Review.
-
Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.Drugs. 2008;68(1):85-104. doi: 10.2165/00003495-200868010-00006. Drugs. 2008. PMID: 18081374 Review.
-
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.Ther Adv Cardiovasc Dis. 2013 Dec;7(6):322-42. doi: 10.1177/1753944713513061. Ther Adv Cardiovasc Dis. 2013. PMID: 24327730 Free PMC article. Review.
-
Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.Blood Purif. 2014;37(4):316-24. doi: 10.1159/000365746. Epub 2014 Aug 27. Blood Purif. 2014. PMID: 25171148
Cited by
-
Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.Gastroenterology. 2016 Oct;151(4):733-746.e12. doi: 10.1053/j.gastro.2016.06.022. Epub 2016 Jun 21. Gastroenterology. 2016. PMID: 27342212 Free PMC article.
-
The deposition of lanthanum carbonate may activate macrophages to induce gastrointestinal mucosal injury in patients with chronic kidney disease: an in vitro caco-2/THP-1 macrophage coculture model study.J Biol Inorg Chem. 2024 Feb;29(1):101-112. doi: 10.1007/s00775-023-02033-x. Epub 2023 Dec 26. J Biol Inorg Chem. 2024. PMID: 38148422
-
Calcitriol-mediated hypercalcemia secondary to granulomatous disease caused by soft-tissue filler injection: a case report.Clin Cases Miner Bone Metab. 2017 Sep-Dec;14(3):340-346. doi: 10.11138/ccmbm/2017.14.3.340. Epub 2017 Dec 27. Clin Cases Miner Bone Metab. 2017. PMID: 29354165 Free PMC article.
-
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?Drugs. 2017 Jul;77(11):1155-1186. doi: 10.1007/s40265-017-0758-5. Drugs. 2017. PMID: 28584909 Review.
-
Histopathological lesions of the gastrointestinal tract associated with the use of polystyrene sulfonate and sevelamer: a meta-analysis.Pathologica. 2024 Aug;116(4):216-221. doi: 10.32074/1591-951X-994. Pathologica. 2024. PMID: 39377503 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical